Allergy Therapeutics Past Earnings Performance
Past criteria checks 0/6
Allergy Therapeutics's earnings have been declining at an average annual rate of -72.7%, while the Pharmaceuticals industry saw earnings declining at 1.7% annually. Revenues have been declining at an average rate of 5.2% per year.
Key information
-72.7%
Earnings growth rate
-65.9%
EPS growth rate
Pharmaceuticals Industry Growth | 14.1% |
Revenue growth rate | -5.2% |
Return on equity | -189.8% |
Net Margin | -94.3% |
Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses BreakdownBeta
How Allergy Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 53 | -50 | 45 | 23 |
30 Sep 23 | 56 | -47 | 47 | 22 |
30 Jun 23 | 60 | -43 | 49 | 20 |
31 Mar 23 | 62 | -36 | 49 | 20 |
31 Dec 22 | 64 | -29 | 48 | 19 |
30 Sep 22 | 68 | -21 | 48 | 17 |
30 Jun 22 | 73 | -14 | 47 | 16 |
31 Mar 22 | 76 | -10 | 47 | 14 |
31 Dec 21 | 79 | -5 | 48 | 13 |
30 Sep 21 | 82 | -1 | 47 | 13 |
30 Jun 21 | 84 | 3 | 46 | 13 |
31 Mar 21 | 83 | 5 | 45 | 11 |
31 Dec 20 | 82 | 7 | 45 | 9 |
30 Sep 20 | 80 | 7 | 45 | 9 |
30 Jun 20 | 78 | 7 | 45 | 9 |
31 Mar 20 | 78 | 8 | 45 | 11 |
31 Dec 19 | 77 | 8 | 45 | 12 |
30 Sep 19 | 76 | 6 | 45 | 13 |
30 Jun 19 | 74 | 3 | 45 | 13 |
31 Mar 19 | 73 | 0 | 44 | 14 |
31 Dec 18 | 73 | -3 | 43 | 15 |
30 Sep 18 | 71 | -5 | 43 | 16 |
30 Jun 18 | 68 | -8 | 43 | 16 |
31 Mar 18 | 67 | -5 | 42 | 14 |
31 Dec 17 | 66 | -3 | 42 | 11 |
30 Sep 17 | 65 | -3 | 41 | 10 |
30 Jun 17 | 64 | -2 | 41 | 9 |
31 Mar 17 | 62 | -5 | 39 | 11 |
31 Dec 16 | 60 | -7 | 37 | 14 |
30 Sep 16 | 54 | -10 | 34 | 15 |
30 Jun 16 | 49 | -13 | 30 | 16 |
31 Mar 16 | 46 | -10 | 29 | 12 |
31 Dec 15 | 44 | -6 | 28 | 9 |
30 Sep 15 | 44 | -3 | 28 | 6 |
30 Jun 15 | 43 | 0 | 27 | 3 |
31 Mar 15 | 43 | 1 | 27 | 3 |
31 Dec 14 | 43 | 2 | 26 | 3 |
30 Sep 14 | 42 | 1 | 26 | 3 |
30 Jun 14 | 42 | 1 | 26 | 3 |
31 Mar 14 | 41 | 1 | 25 | 3 |
31 Dec 13 | 41 | 2 | 25 | 3 |
30 Sep 13 | 40 | 1 | 25 | 3 |
30 Jun 13 | 39 | 1 | 24 | 3 |
Quality Earnings: AGY is currently unprofitable.
Growing Profit Margin: AGY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AGY is unprofitable, and losses have increased over the past 5 years at a rate of 72.7% per year.
Accelerating Growth: Unable to compare AGY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AGY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.8%).
Return on Equity
High ROE: AGY has a negative Return on Equity (-189.77%), as it is currently unprofitable.